WCN25-2664 Low-dose versus Standard-dose cyclical Cyclophosphamide and Steroids in the treatment of Primary Membranous Nephropathy- a randomized controlled trial
Both cyclical cyclophosphamide (CYC) with corticosteroids (CS) and rituximab are recommended as first-line therapies for patients with primary membranous nephropathy (MN). However, the high doses of CYC and CS associated with this regimen raise significant concerns. Additionally, several retrospective studies suggest that a lower dose of CYC/CS may effectively induce remission in MN patients. Therefore, this study aimed to assess whether the lower dose of cyclical CYC/CS was non-inferior to the standard dose of CYC/CS in patients with MN.
Authors
- Raja Ramachandran (ORCID: https://orcid.org/0000-0002-1273-9107)
- Harbir Singh Kohli (ORCID: https://orcid.org/0000-0003-4806-2297)
- Manisha Sahay (ORCID: https://orcid.org/0000-0001-5534-2516)
- Vivekanand Jha (ORCID: https://orcid.org/0000-0002-8015-9470)
- Joyita Bharati (ORCID: https://orcid.org/0000-0003-1401-8159)
- Vinod Kumar (ORCID: https://orcid.org/0000-0003-3733-4197)
- Prabhat Chauhan (ORCID: https://orcid.org/0000-0001-5876-9232)
- Indranil Ghosh
- Vivek Sood
Institutions
- Boston Medical Center (US)
- INHS Asvini (IN)
- George Institute for Global Health (IN)
- Command Hospital (IN)
- Army Hospital Research and Referral (IN)
- Post Graduate Institute of Medical Education and Research (IN)
- Osmania Medical College (IN)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.ekir.2024.11.410
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00